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Abstract
Aims Heart failure (HF) guidelines place patients into 3 discrete groups according to left ventricular ejection fraction (LVEF):
reduced (<40%), mid-range (40–49%), and preserved LVEF (≥50%). We assessed whether clinical phenogroups offer better
prognostication than LVEF.
Methods and results This was a sub-study of the Patient-Centered Care Transitions in HF trial. We analysed baseline char-
acteristics of hospitalized patients in whom LVEF was recorded. We used unsupervised machine learning to identify clinical
phenogroups and, thereafter, determined associations between phenogroups and outcomes. Primary outcome was the com-
posite of all-cause death or rehospitalization at 6 and 12 months. Secondary outcome was the composite cardiovascular death
or HF rehospitalization at 6 and 12 months. Cluster analysis of 1693 patients revealed six discrete phenogroups, each charac-
terized by a predominant comorbidity: coronary heart disease, valvular heart disease, atrial fibrillation (AF), sleep apnoea,
chronic obstructive pulmonary disease (COPD), or few comorbidities. Phenogroups were LVEF independent, with each
phenogroup encompassing a wide range of LVEFs. For the primary composite outcome at 6 months, the hazard ratios (HRs)
for phenogroups ranged from 1.25 [95% confidence interval (CI) 1.00–1.58 for AF] to 2.04 (95% CI 1.62–2.57 for COPD)
(log-rank P < 0.001); and at 12 months, the HRs for phenogroups ranged from 1.15 (95% CI 0.94–1.41 for AF) to 1.87 (95%
1.52–3.20 for COPD) (P < 0.002). LVEF-based classifications did not separate patients into different risk categories for the pri-
mary outcomes at 6 months (P = 0.69) and 12 months (P = 0.30). Phenogroups also stratified risk of the secondary composite
outcome at 6 and 12 months more effectively than LVEF.
Conclusion Among patients hospitalized for HF, clinical phenotypes generated by unsupervised machine learning provided
greater prognostic information for a composite of clinical endpoints at 6 and 12 months compared with LVEF-based categories.
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Introduction
Current guidelines for the diagnosis and treatment of heart
failure (HF) classify patients into three groups according to
left ventricular (LV) ejection fraction (LVEF).1,2 An LVEF of
40–49% (mid-range LVEF [mrEF]) is used to separate patients
with HF and reduced ejection fraction (HFrEF; LVEF <40%)
from those with HF and preserved ejection fraction (HFpEF;
LVEF ≥50%), although the HFmrEF category is much debated,
with some arguing for HFrEF and HFpEF to meet at an LVEF of
45%.3 Regardless, these cut-offs were established because
patients with a lower LVEF have higher mortality and risk of
hospitalization.4 Most large randomized trials in HF restricted
their population to patients with an LVEF below 40% to max-
imize event rates, an approach which has shown important
clinical benefit for several drugs and devices.5 In society
guidelines, these therapies have accordingly been recom-
mended for HFrEF patients,1,2 while current evidence indi-
cates that many treatments are effective in HF patients
with LVEF well above 40%.6–9
While LVEF remains an informative characteristic for ther-
apeutic decisions in HF, emerging data suggest that classify-
ing patients with HF according to LVEF categories has
several disadvantages. There are shared epidemiological fea-
tures between patients with HFrEF, HFmrEF, and HFpEF, and
pathophysiologic mechanisms may not be mutually
exclusive.5 In addition, LVEF measurement varies greatly
among methods and observers,10 and LVEF alone is not a
good predictor of adverse outcomes.11 Alternatively, HF can
be considered a heterogeneous syndrome in which disease
progression is associated with a dynamic evolution of func-
tional and structural changes, leading to unique disease tra-
jectories, and creating a spectrum of phenogroups with
overlapping and distinct characteristics.12 However, clear evi-
dence that characteristics of HF patients form a continuum
across LVEF is still lacking. Also, the role of comorbidities in
classification of HF is uncertain as comorbidities are
underreported in HF trials.13
Novel data-driven methods have been developed for clas-
sification or phenotyping of complex chronic medical disor-
ders, incorporating recent advances in artificial
intelligence.14 These alternative classification methods have
been applied to patients with HF and were found to be supe-
rior to LVEF-based classification in characterizing patient
subgroups.15–19
In this study, we aimed to identify distinct clinical
phenogroups among patients with HF using unsupervised
machine learning analysis. Unsupervised machine learning
looks for historically undetected patterns in a dataset without
human-labelled data or supervision. We hypothesized that a
phenotype-based classification system would be more effec-
tive than guideline-recommended LVEF categories in
predicting outcomes following hospital discharge.
Methods
Population
This was a sub-study of the Patient-Centered Care Transi-
tions in HF (PACT-HF) multicentre stepped wedge cluster
randomized clinical trial,20,21 which enrolled 2494 adults
hospitalized for HF across 10 tertiary or quaternary care ur-
ban hospitals in Ontario, Canada. Patients were included if
HF was considered the primary reason for hospitalization,
and if rule-out criteria for HF were not met. Rule-out
criteria were as follows: Boston criteria <5, and/or B type
natriuretic peptide <50 pg/mL or N-terminal pro brain na-
triuretic peptide (NT-proBNP) <300 pg/mL.1,22 Hospitals
were randomized to sequentially deliver an intensive
patient-centred transitional care program or usual care.20
The primary and secondary clinical outcomes have been
reported.21
This study complies with the Declaration of Helsinki. Be-
cause services were evidence-informed and considered qual-
ity improvement, the PACT-HF study protocol was approved
by all institutional research ethics boards with waiver of writ-
ten consent. Patients provided verbal informed consent for
study participation.19 The use of data in this project was au-
thorized under section 45 of Ontario’s Personal Health Infor-
mation Protection Act, which does not require review by a
Research Ethics Board.
Measurements
Only baseline values were included to create a
cross-sectional sample. Trained nurse clinicians extracted
laboratory values and LVEF from charts and transmitted
them to the study centre via electronic case report forms.
LVEF values were obtained from the most recent echocar-
diogram or radionuclide ventriculogram during the preced-
ing 12 months. Baseline demographics and clinical
characteristics were extracted from administrative databases
using a 5 year lookback (supporting information, Table S1).
Comorbidities were extracted using International Classifica-
tion of Diseases-10 codes. Using unique encoded identifiers,
clinical trial data were linked to the administrative databases
(e.g. Canadian Institute for Health Information) accessed at
ICES (formerly known as the Institute for Clinical Evaluative
Sciences).20 ICES is an independent, non-profit research in-
stitute whose legal status under Ontario’s health informa-
tion privacy law allows it to collect and analyse health care
and demographic data, without consent, for health system
evaluation and improvement. These datasets (supporting in-
formation, Table S1) were linked using unique encoded iden-
tifiers and analysed at ICES.
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Outcomes
Primary outcome was the first occurrence of all-cause death
or all-cause rehospitalization at 6 and 12 months. Second-
ary outcome was the first occurrence of cardiovascular
death or HF rehospitalization at 6 and 12 months. All
outcomes were measured relative to the discharge date of
the index HF hospitalization, defined as the first unplanned
hospitalization for HF in a participating hospital during the
study period.20
Statistical analysis
Baseline characteristics were summarized using mean and
standard deviation (SD) or median and interquartile range
(IQR) for continuous variables, and count and percentages
for categorical variables. Baseline characteristics were com-
pared using one-way analysis of variance, Kruskal–Wallis test
or χ2 test where appropriate.
Each baseline characteristic was assessed for an associa-
tion with LVEF using Spearman’s rank correlation coefficient
(r) and univariable linear regression analysis reporting mean
difference, 95% confidence intervals (CIs), and R2 value.
Given that LVEF was not normally distributed, the analysis
was repeated with LVEF values categorized per 10% using in-
terval regression analysis, obtaining a pseudo R2 value. A
multivariable linear regression model was constructed with
clinically relevant, independent baseline variables. Mean dif-
ferences were reported with 95% CIs, and a two-sided P value
of 0.05 was considered to be significant. Associations were
defined as strong, moderate, or weak based on a Spearman’s
r value of >0.5, 0.5–0.3, or <0.3 respectively.
Cluster analysis
We included all independent variables in the dataset for fur-
ther analysis: age, sex, weight, systolic blood pressure, glu-
cose, creatinine, sodium, NT-proBNP, troponin I, and history
of hypertension, atrial fibrillation (AF), chronic obstructive
pulmonary disease (COPD), severe valvular disease, and coro-
nary revascularization. We did not consider the Charlson co-
morbidity index in the clustering analysis, as it encapsulates
comorbidities already included in our analysis. We did not in-
clude classes of medication as these are typically prescribed
based on LVEF. R v3.6.3 (R Foundation for Statistical Comput-
ing) and SAS v9.4 (SAS Institute) were used for machine learn-
ing and statistical analyses, respectively. Clustering of
baseline characteristics was performed (i) independent of
LVEF, (ii) according to guideline-recommended categories of
LVEF (<40, 40–49, and ≥50), and (iii) dividing LVEF in catego-
ries per 10% (<20, 20–29, 30–39, 40–49, 50–59, and ≥60).
Gower’s distance metric, which can handle categorical
variables and missing values, was used to construct a dissim-
ilarity matrix that served as an input to our clustering analy-
sis, providing a pairwise comparison of observations. For
missing values, two cases were compared if there was at least
one variable where both had correct values. A majority of
variables had <3% missing values. We performed agglomera-
tive hierarchical clustering with Ward linkage (cluster R pack-
age). We used the elbow method, Dunn statistic, silhouette
coefficient, and Hubert index (factoextra R package) to deter-
mine the optimal number of clusters. We constructed
heatmaps using the ComplexHeatmap R package. We
compared the performance of each of the 3 clustering
approaches using six metrics to evaluate cluster stability, co-
hesion, separation, and information gain between analyses
(details in Table S4 legend).
Survival analysis
We generated Kaplan–Meier survival curves for each clinical
outcome and grouping and compared curves using the
log-rank test. We estimated hazard ratios (HRs) and CI, ad-
justed for age and sex, using Cox proportional hazards
models. Violation of the proportional hazards assumption
was determined through the analysis of Martingale residuals.
Results
Population characteristics
We included 1693 patients with available LVEF data in the
analysis. LVEF was recorded at a median of 1 day
post-admission to hospital (IQR 45 days pre-admission, to
3 days post-admission). Baseline characteristics of the study
population are displayed in Table 1. Mean [SD] age was 77
[12] years, and 49% of the patients were female. Hyperten-
sion (76%), AF (57%), and diabetes (52%) were the most
common comorbidities. Median (IQR) LVEF was 49 (33–58)
percent. LVEF was abnormally distributed, with the histogram
showing a peak at LVEF 50–54% (Figure S1).
Establishing phenogroups through clustering
analysis
Clustering analysis of individual patients in an
LVEF-independent analysis identified six clusters as the opti-
mal number of groupings (Figure S2). Patient characteristics
stratified according to these six phenogroups are displayed
in Figure 1A and Table 1. Most phenogroups showed a high
prevalence of a specific comorbidity: coronary artery disease
(CAD, 54%, Phenogroup 1), valvular heart disease (VHD,
100%, Phenogroup 2), AF (94%, Phenogroup 4), COPD
Clinical phenogroups in heart failure 3
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(100%, Phenogroup 5), and obstructive sleep apnoea (OSA,
100%, Phenogroup 6). Phenogroup 3 only had hypertension
and diabetes as comorbidities (66% and 50%, respectively),
labelled ‘few comorbidities’. Although LVEF significantly
differed between groups, there was no clear between-group
clinical separation according to traditional LVEF categories:
LVEF of most phenogroups ranged between 30% and 55%,
except the AF phenogroup, which had a significantly
higher LVEF than Phenogroups 1 through 5 (all P < 0.001,
Figure S3) and the CAD phenogroup, which had a
significantly lower LVEF than the AF, OSA, and COPD
phenogroups (P < 0.001, P = 0.016, and P = 0.004, respec-
tively, Figure S3).
Associations between clinical characteristics and
left ventricular ejection fraction
Clustering analysis of characteristics and their association
with the 3 guideline-recommended LVEF categories (<40%,
Figure 1 Heatmaps of characteristics (rows) and LVEF categories (columns) of 1693 patients. (A) Patient characteristics stratified according to clusters
identified by an unbiased, LVEF-independent approach. (B) Patient characteristics stratified according to the three guideline-recommended LVEF cat-
egories, reduced, mid-range, and preserved EF. (C) Patient characteristics stratified according to six LVEF categories (per 10%). Darker means higher
value, lighter means lower value. AF, atrial fibrillation; CAD, coronary artery disease, COPD, chronic obstructive pulmonary disease; EF, ejection frac-
tion; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro brain natriuretic peptide; OSA, obstructive sleep apnoea; PCI/CABG, percuta-
neous coronary intervention or coronary artery bypass grafting; VHD, valvular heart disease.
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40–49%, >50%) and 6 LVEF categories in per 10% increments
is shown in Figure 1B-C and Table S2. Relative to LVEF > 50,
LVEF <50% was associated with higher concentrations of
NT-proBNP (P < 0.001) and troponin (P < 0.001), and more
prevalent history of coronary revascularization (P < 0.001,
Table S2). LVEF >50% was associated with older age
(P < .001), higher percentage of women (P < 0.001), and
higher prevalence of AF (P < 0.001) relative to those with
LVEF <50% (Table S2).
Accordingly, in univariable linear regressions LVEF had a
significant positive association with sex, age, systolic blood
pressure, presence of AF, and presence of hypertension,
and a significant negative association with NT-proBNP and
history of coronary revascularization (Table 2). However, the
associations were weak, with r values <0.3 (Table 2). In
multivariable linear regression analysis, age, systolic blood
pressure, glucose, sodium, NT-proBNP, and female sex had
significant associations with LVEF (Table S3).
Cluster separation and stability
Comparative statistics for the clustering analyses demon-
strated that the LVEF-independent analysis provided the
most separated clusters, but at the cost of cluster stability
(Table S4). The LVEF-independent analysis demonstrated
the highest information gain when compared with three
and six LVEF categories (Table S4), which means that the
LVEF-independent categorization has less ‘uncertainty’ or
‘noise’. The use of three LVEF categories resulted in an
intermediate separation of clusters, with some overlap be-
tween categories, but the most ‘stable’ categorization of HF
patients. This stability means that in a slightly different pop-
ulation (e.g. missing 1% of subjects), likely the same categori-
zation would be obtained for the remaining subjects. The use
of six LVEF categories had the lowest phenogroup cohesion
and separation between categories and intermediate stability
(Table S4).
Left ventricular ejection fraction and
phenogroup-based classifications and outcomes
The phenogroup-based HF classification successfully stratified
patients according to clinical outcomes (Table 3, Figures 2, 3,
S4, and S5). For the primary composite outcome of all-cause
death or rehospitalization at 6 months, the HRs for the
phenogroups that ranged from 1.25 (95% CI 1.00–1.58 for
phenogroup AF) to 2.04 (95% CI 1.62–2.57 for phenogroup
COPD) (log-rank P < 0.001, Figure 2A). For the primary com-
posite outcome at 12 months, the HRs for phenogroups
ranged from 1.15 (95% CI 0.94–1.41 for phenogroup AF) to
1.87 (95% CI 1.52–2.30 for phenogroup COPD) (P < 0.002,
Figure 3A). For the secondary composite outcome of cardio-
vascular death or HF rehospitalization at 6 months, the HRs
for phenogroups ranged from 1.15 (95% CI 0.85–1.56 for
phenogroup CAD) to 1.68 (95% CI 1.19–2.36 for phenogroup
VHD) (P = 0.002, Figure S4A); and at 12 months, the HRs
ranged from 1.15 (95% CI 0.88–1.51 for phenogroup CAD)
to 1.84 (95% CI 1.35–2.50 for phenogroup OSA) (P < 0.001,
Table 2 Univariable associations of baseline characteristics and left ventricular ejection fraction
Clinical characteristics
Mean difference





Age, years 0.31 (0.25–0.37) <0.001 0.222 0.063 0.067 0.055
Female 6.89 (5.51–8.28) <0.001 0.229 0.005 0.050 0.046
Weight, kgc 0.01 (0.16 to 0.17) 0.923 0.017 <0.001 <0.001 <0.001
Systolic blood pressure, mmHgc 1.23 (0.96–1.49) <0.001 0.214 0.046 0.042 0.038
Comorbidities
Atrial fibrillation 2.37 (0.94–3.80) 0.001 0.072 0.006 0.007 0.004
Cerebrovascular disease 1.89 (0.46 to 4.23) 0.115 0.038 0.002 0.002 0.002
COPD 3.09 (1.45–4.74) <0.001 0.088 0.008 0.007 0.007
Diabetes 1.05 (0.37 to 2.47) 0.148 0.038 0.001 0.001 0.002
PCI/CABG 2.63 (4.17 to 1.08) 0.001 0.089 0.007 0.005 0.005
Severe valvular heart disease 0.41 (1.39 to 2.22) 0.655 0.008 <0.001 <0.001 <0.001
Sleep apnoea 0.60 (1.61 to 2.82) 0.592 0.017 <0.001 0.001 <0.001
Laboratory analysis
Creatinine, μmol/Lc 0.02 (0.09 to 0.06) 0.680 0.004 <0.001 <0.001 <0.001
Sodium, mmol/L 0.03 (0.18 to 0.11) 0.652 0.014 <0.001 <0.001 <0.001
Troponin I, ng/L 0.38 (0.75 to 0.01) 0.050 0.257 0.004 0.005 0.005
NT-proBNP, ng/Ld 0.04 (0.05 to 0.03) <0.001 0.282 0.003 0.028 0.029
CI, confidence interval; COPD, chronic obstructive pulmonary disease; NT-proBNP, N-terminal pro brain natriuretic peptide.
*Mean difference and confidence intervals, R2 value, and P value derived from univariable linear regression analysis.
ar value derived from correlation analysis.
bPseudo R2 value derived from interval regression analysis (six left ventricular ejection fraction categories using per 10% cut-offs).
cPer a unit of 10.
dPer a unit of 100.
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Figure S5A). Patients with COPD (Phenogroup 5) had the
worst outcomes: 69% of patients died or were rehospitalized
at 6 months, 79% at 12 months (Table 3, Figure 2A). Patients
with no major comorbidity (Phenogroup 3) had the best
outcomes: 44% of patients died or were rehospitalized
at 6 months, 59% at 12 months. Results were similar for
the secondary outcomes (Table 3, Figures S4 and S5), demon-
strating early identification of risk using phenogroup
classification.
LVEF-based groupings—either three or six categories—
did not stratify clinical outcomes well, whether at 6 or
12 month outcomes (all P > 0.05, Table 3, Figures 2B,C, 3B,
C, S4B,C, and S5B,C). The exception was LVEF ≥50% in the
three-class grouping, which showed significantly less cardio-
vascular deaths or HF readmissions (HR 0.75, CI 0.62–0.92,
P = 0.005).
Discussion
In this cohort of 1693 patients hospitalized for HF and en-
rolled in the Patient-Centered Care Transitions in HF
multicentre randomized clinical trial, we found that an unsu-
pervised machine learning approach separated patients ac-
cording to different comorbidity profiles or phenogroups,
each of which included patients across the LVEF spectrum.
The classification of patients by clinical phenogroups and in-
dependent of LVEF resulted in greater separation of clusters
and better association with clinical outcomes at 6 and
12 months than classification based on LVEF categories. This
pertained to both all-cause and HF readmissions, and
all-cause and CV death. These results suggest that classifying
HF patients based on clinical characteristics rather than LVEF
categories provides relevant prognostic information, and that

















Composite of all-cause death or rehospitalization at
6 months
Composite of all-cause death or rehospitalization at
12 months
1 CAD 232 (54) 1.32 (1.05–1.64) 0.015 <0.001 282 (65) 1.22 (1.00–1.48) 0.045 <0.001
2 VHD 116 (67) 1.88 (1.46–2.42) <0.001 134 (78) 1.70 (1.35–2.14) <0.001
3 None 130 (44) Reference 175 (59) Reference
4 AF 206 (56) 1.25 (1.00–1.58) 0.054 249 (67) 1.15 (0.94–1.41) 0.174
5 COPD 173 (69) 2.04 (1.62–2.57) <0.001 199 (79) 1.87 (1.52–2.30) <0.001
6 OSA 99 (59) 1.63 (1.25–2.12) <0.001 127 (76) 1.66 (1.32–2.09) <0.001
LVEF, 3 categories
<40% 314 (55) Reference 0.687 377 (66) Reference 0.300
40–49% 157 (56) 0.96 (0.79–1.17) 0.711 194 (69) 1.01 (0.85–1.20) 0.906
≥50% 485 (58) 1.01 (0.87–1.17) 0.938 595 (71) 1.06 (0.93–1.21) 0.408
LVEF, 6 categories
<20% 22 (44) Reference 0.401 28 (56) Reference 0.338
20–29% 145 (57) 1.46 (0.93–2.29) 0.096 172 (68) 1.39 (0.93–2.08) 0.105
30–39% 147 (54) 1.27 (0.81–2.00) 0.291 177 (65) 1.23 (0.82–1.83) 0.316
40–49% 157 (56) 1.28 (0.82–2.01) 0.281 194 (69) 1.29 (0.86–1.92) 0.213
50–59% 274 (57) 1.28 (0.82–1.98) 0.275 344 (71) 1.32 (0.90–1.95) .160
≥60% 211 (60) 1.42 (0.91–2.22) 0.121 251 (72) 1.39 (0.93–2.06) 0.104
Phenogroups
Composite of cardiovascular death or
HF rehospitalization at 6 months
Composite of cardiovascular death or
HF rehospitalization at 12 months
1 CAD 121 (28) 1.15 (0.85–1.56) 0.360 0.002 146 (34) 1.15 (0.88–1.51) 0.304 <0.001
2 VHD 65 (38) 1.68 (1.19–2.36) 0.003 80 (46) 1.75 (1.29–2.38) <0.001
3 None 71 (24) Reference 89 (30) Reference
4 AF 106 (29) 1.17 (0.85–1.61) 0.328 143 (39) 1.27 (0.96–1.68) 0.091
5 COPD 89 (36) 1.63 (1.19–2.24) 0.002 115 (46) 1.77 (1.34–2.35) <0.001
6 OSA 55 (33) 1.58 (1.11–2.25) 0.012 78 (47) 1.84 (1.35–2.50) <0.001
LVEF, 3 categories
<40% 192 (33) Reference 0.075 238 (41) Reference 0.180
40–49% 80 (28) 0.78 (0.60–1.01) 0.063 101 (36) 0.80 (0.63–1.01) 0.056
≥50% 235 (28) 0.75 (0.62–0.92) 0.005 312 (37) 0.81 (0.68–0.97) 0.019
LVEF, 6 categories
<20% 17 (34) Reference 0.096 23 (46) Reference 0.193
20–29% 93 (37) 1.08 (0.64–1.81) 0.779 111 (44) 0.95 (0.61–1.49) 0.829
30–39% 82 (30) 0.79 (0.46–1.33) 0.367 104 (38) 0.73 (0.46–1.15) 0.170
40–49% 80 (28) 0.72 (0.42–1.22) 0.217 101 (36) 0.67 (0.42–1.05) 0.083
50–59% 141 (29) 0.71 (0.42–1.18) 0.184 187 (39) 0.70 (0.45–1.08) 0.110
≥60% 94 (27) 0.67 (0.40–1.14) 0.139 125 (36) 0.65 (0.41–1.03) 0.065
AF, atrial fibrillation; CAD, coronary artery disease; CI, confidence interval; COPD, chronic obstructive pulmonary disease; OSA, obstructive
sleep apnoea; LVEF, left ventricular ejection fraction; VHD, valvular heart disease.
*Adjusted for age and sex.
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Figure 2 Survival curves of heart failure patients stratified according to LVEF-based classifications or LVEF-independent phenogroup-based classifica-
tion. Survival curves for all-cause death or rehospitalization at 6 months, adjusted for age and sex. P value from log-rank test. Survival differs signif-
icantly across groups using the LVEF-independent phenogroup-based classification (A) but not in LVEF-based classifications (B,C). (A) Kaplan–Meier
curves stratified according to phenogroups. (B) Kaplan–Meier curves stratified according to the three guideline-recommended LVEF categories, re-
duced, mid-range, and preserved EF. (C) Kaplan–Maier curves according to six LVEF categories (per 10%). AF, atrial fibrillation; CAD, coronary artery
disease; COPD, chronic obstructive pulmonary disease; EF, ejection fraction; LVEF, left ventricular ejection fraction; OSA, obstructive sleep apnoea;
VHD, valvular heart disease.
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Figure 3 Survival curves of heart failure patients stratified according to LVEF-based classifications or LVEF-independent phenogroup-based classifica-
tion. Survival curves for all-cause death or rehospitalization at 12 months, adjusted for age and sex. P value from log-rank test. Survival differs signif-
icantly across groups using the LVEF-independent phenogroup-based classification (A) but not in LVEF-based classifications (B,C). (A) Kaplan–Meier
curves stratified according to phenogroups. (B) Kaplan–Meier curves stratified according to the three guideline-recommended LVEF categories, re-
duced, mid-range, and preserved EF. (C) Kaplan–Meier curves according to six LVEF categories (per 10%). AF, atrial fibrillation; CAD, coronary artery
disease; COPD, chronic obstructive pulmonary disease; EF, ejection fraction; LVEF, left ventricular ejection fraction; OSA, obstructive sleep apnoea;
VHD, valvular heart disease.
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comorbidities are major drivers of outcomes in HF patients.
Figure 4 summarizes our findings.
The LVEF has served as an inclusion criterion for HF clinical
trials, is recommended in guidelines to classify HF, and is a
practical parameter to guide treatment decisions in HF; how-
ever, this classification approach has some disadvantages.
First, LVEF estimates vary between techniques and repeat
measurements, but are often treated as absolute.10,23 Pa-
tients with an LVEF just above an established threshold for
treatment may be denied HF therapies without recognition
of the variation in LVEF estimates. Second, many epidemio-
logical, pathophysiological, and clinical features are shared
between patients with HFrEF, HFmrEF, and HFpEF. Similar
pathophysiologic mechanisms across the LVEF spectrum in-
clude endothelial dysfunction, neurohumoral activation,
myocardial fibrosis, and skeletal myopathy, among others.5,24
Abnormalities of diastolic function are universally present in
HFrEF, and systolic dysfunction—as evidenced by a reduction
of global longitudinal strain and cardiac output reserve—is
often present in HFpEF.25 Activation of the renin–angioten-
sin–aldosterone system is not restricted to HFrEF,26 yet ther-
apies targeting the renin–angiotensin–aldosterone system
are largely recommended for those with LVEF <40% based
on the inclusion criterion used in historic HF trials.5 Third,
the relation of lower LVEF with increased mortality is only
maintained until an LVEF of 45%. Above this value, LVEF is
an unreliable prognosticator of mortality.4 This may be due,
in part, to increasing heterogeneity and varying pathophysiol-
ogy among patients at the higher end of the LVEF
spectrum.27
Our LVEF-independent, phenotype-driven approach pro-
vided the most information about patients, facilitated better
separation between groups of patients (Figure 1A, Table S4),
and better identified patients at risk for all-cause rehospitali-
zation and death as well as HF rehospitalization and CV death
than LVEF-based groupings (Table 3, Figure 2, 3, S4, and S5).
Our analysis confirms that comorbidities are a major driver of
outcomes, regardless of LVEF. Our findings are consistent
with previous studies that demonstrated an association be-
tween underlying comorbidities and outcomes in HF.28–31
Among patients with HF, those with CAD had a similar mor-
tality risk but increased risk of HF hospitalization as those
without CAD32; those with AF had an increased risk of mortal-
ity than those without AF30; and those with COPD and OSA
had and increased risk of mortality than those without COPD
or OSA.28,29 These associations were often independent of
LVEF.33
We recognize that any phenogroup classification system
that labels categories on the basis of a single comorbidity is
simplistic and that comorbidities overlap between groups.33
For example, the prevalence of AF in the VHD phenogroup
was 61%, and the prevalence of CAD in the COPD and OSA
Figure 4 Summary of the study findings. We analysed baseline characteristics of 1693 patients with heart failure included in the Patient-Centered Care
Transitions in Heart Failure randomized clinical trial. Clustering analysis independent of LVEF, better separated survival curves, provided more infor-
mation and less overlap of clinical phenogroups compared to guideline-recommended subdivision in three LVEF-based categories. Through clustering
analysis, we found six clinical phenogroups mainly based on comorbidities. COPD, chronic obstructive pulmonary disease; HFmrEF, heart failure with
mid-range ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; HR, hazard ratio;
LVEF, left ventricular ejection fraction.
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groups was approximately 37%. This reflects the high burden
of comorbidities in patients hospitalized with HF. However,
the clustering algorithm determined, in an unsupervised
manner, that patients with concurrent VHD and AF are more
similar to patients with VHD alone than to patients with AF
alone. The outcome analysis confirms that outcomes of HF
patients with VHD (with or without AF) are significantly
worse than outcomes of HF patients with AF (and no VHD).
Our approach differs from prior approaches, which
used artificial intelligence to provide a better separation of
categories in patients with HF, but results are consistent
overall.15–18,34 Some of the previous models were trained a
priori to predict clinical outcomes, thus satisfying a
self-fulfilling prophecy: groupings were based on clinical
outcomes, and naturally performed better than LVEF at
prediction.18 The phenogroup approach in prior studies was
also limited by the need to input dozens of complex variables
to classify a patient.16,18,19 Our analysis is different as it only
included baseline patient characteristics—and not outcomes
—in the clustering model; thus, it was not designed to predict
outcomes. However, subsequent linkages to clinical outcomes
proved that this unbiased, LVEF-independent classification
was superior to LVEF-based classification in predicting out-
comes. Additionally, our randomized clinical trial database
provided granular characteristics, including contemporane-
ous LVEF and a 5 year lookback of comorbidities. Finally,
linkage to provincial databases provided a wealth of clinical
outcomes (all-cause, CV, and HF events), while previous
registry-type datasets were typically limited to all-cause
death.
The goal of our analysis was not to develop a risk
prediction model, but to explore HF phenotypes and their
associations with outcomes relative to an LVEF based classifi-
cation system. As such, we did not formally compare our
phenotype-based approach to existing risk scores. The perfor-
mance of this phenotype-based classification scheme relative
to validated risk models in HF35,36 is unknown and the subject
of further investigation. We have demonstrated in a prior
work that simple clinical risk prediction indices can predict
clinical outcomes with similar or better performance than
complex and validated risk prediction scores in HF,37,38 and
it is possible that this simple phenotype-based classification
scheme may also compare favourably.
Our findings have important applications. The external
validation of our classification scheme is underway, and the
results will inform the development of a decision tree to
guide the risk assessment in patients hospitalized with HF.
The classification scheme may also be useful to select sub-
groups of patients who are likely to respond to HF therapies
in clinical trials, particularly within traditional categories that
have been difficult to demonstrate treatment efficacy in. For
example, few therapeutic options exist for patients with
HFmrEF and HFpEF, and phenotype-based selection criteria
may be an effective way to facilitate homogeneity and
response to targeted treatments in clinical trials.39,40 We de-
scribe several phenogroups at higher risk of cardiovascular
events, across the LVEF spectrum, which could inform design
of future trials. Whether certain phenogroups respond differ-
ently to guideline-directed medical therapy remains unknown
but possible, and this should be explored in future trials.
This study has some limitations. First, LVEF was sometimes
obtained from a recent—rather than current—echocardio-
gram or nuclear ventriculogram. Second, we included a rela-
tively large amount of categorical variables, which limited the
number of combinations that can be produced in a hierarchy.
Incorporation of more baseline characteristics, including
other echocardiographic variables, could have further im-
proved cluster-based classification of HF patients. Hierarchi-
cal clustering algorithms such as the one used in this study
tend to prioritize categorical variables over continuous
variables and other clustering algorithms could have been
considered to avoid prioritizing categorical variables.41 We
chose Gower’s distance and hierarchical clustering because
this combination could handle categorical variables and miss-
ing values. This approach combined good prognostic capabil-
ity with ease of application to different HF populations,
without the need for difficult algorithms. Third, event rates
could have been impacted by factors not captured in our da-
tabase, such as adherence to medical therapy and quality of
care. Finally, we realize that our findings may not be general-
izable to other populations. Patients in this pragmatic clinical
trial were hospitalized for HF and may have had a comorbid-
ity profile distinct from those in ambulatory care. External
validation should be performed before clinical application.
Conclusion
In this sub-study of the PACT-HF trial that included patients
hospitalized for HF, we found that unbiased classification of
baseline characteristics through hierarchical cluster analysis
(unsupervised machine learning) resulted in six phenogroups
of patients characterized by different comorbidity profiles.
While there were LVEF differences between phenogroups,
the entire LVEF spectrum was represented in each
phenogroup. The phenogroup classification provided superior
prognostic information for all-cause and CV endpoints at
6 months and 1 year compared with classification based on
three or six LVEF categories. These findings suggest that co-
morbidities are major drivers of prognosis in HF patients.
While LVEF remains a practical tool for therapeutic decision
making in HF, our data suggest that phenogroup-based classi-
fication may better inform the clinician about the risk of
future events. In addition to external validation, future
studies should focus on identifying treatment-responsive
phenogroups in an effort to more precisely guide treatment
decisions.
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